厄洛替尼治疗老年转移性非小细胞肺癌患者的临床观察  

Clinical Observation of Erlotnib in the Treatment of Non-small Cell Lung Cancer with Multimetastases in Elderly Patients

作　　者：张凤[1] 邢丽娜[1] 于有[2] 马艳伟[1] 邹宾英[1] 

机构地区：[1]哈尔滨医科大学附属第二医院肿瘤放疗科,哈尔滨150086 [2]哈尔滨医科大学附属第二医院儿外科,哈尔滨150086

出　　处：《中国肺癌杂志》2009年第12期1242-1246,共5页Chinese Journal of Lung Cancer

摘　　要：背景与目的厄洛替尼是小分子表皮生长因子受体酪氨酸激酶抑制剂,主要用于治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC),本研究探讨厄洛替尼单药治疗老年转移性非小细胞肺癌患者的有效性与安全性。方法33例老年NSCLC多发转移患者接受厄洛替尼150mg/d治疗,服药至疾病进展或死亡。结果共有30例患者可以评价疗效,无病例完全缓解(complete regression,CR),部分缓解(partial regression,PR)6例(20%),稳定(stable disease,SD)16例(53.33%),疾病进展(progressive disease,PD)8例(26.68%)。缓解率(CR+PR)为20.0%;疾病控制率(CR+PR+SD)为73.3%。腺癌组与鳞癌组中位生存期无统计学差异(13.592±1.914个月vs9.846±1.598个月,P=0.301);两组无疾病进展时间无统计学差异(7.367±0.923个月vs6.615±1.366个月,P=0.488)。多因素Cox回归分析显示,有肝脏转移、胸腔积液、脑膜转移是影响厄洛替尼治疗客观疗效而影响生存期的因素。主要不良反应为皮疹和腹泻,不需要特殊处理。结论老年NSCLC多发转移患者对厄洛替尼的治疗能很好耐受,并有一定的生存获益。Background and objective Erlotnib is the inhibitor of epidemic growth factor receptor and mainly used to treat non-small cell lung cancer （NSCLC）.The aim of this study is to evaluate the antitumor efficacy and toxicity of erlotnib in the treatment of Chinese elderly NSCLC patients with multimetastases.Methods Tirty-three Chinese elderly NSCLC patients with multimetastases received 150 mg of erlotnib orally once daily until disease progressing or intolerable toxic developing.Results Tirty patients were evaluable for therpeutic effect.Without complete regression being observed,6 patients got partial resonse （PR,20%）,16 stable disease （SD,53.33%） and 8 progressive disease （PD,26.68%）.The total response rate was 20.0% and disease control rate including both tumor response and stable disease was 73.3%.On the pathology,compared with the patients with squamous cell carcinoma,those with adenocarcinoma had not significant longer median overall （13.592±1.914 months vs 9.846±1.598 months,P=0.301） and progression-free survival times （7.367±0.923 months vs 6.615±1.366 months,P=0.488）,The median survival was sigificantly related with meningeal metastasis,metastasis of liver,pleural efusion using survival analysis.The main toxicities of erlotnib were skin toxicity （rash） and diarrhea with no need of further treatment.Conclusion Erlotnib demonstrates significant antitumor activity and a favorable tolerability profile in Chinese elderly advanced NSCLC patients with multimetastases.

关 键 词：表皮生长因子受体 厄洛替尼 肺肿瘤 老年人 

分 类 号：R734.2[医药卫生—肿瘤]